Senores Pharma Q3 PAT jumps 105% YoY to Rs 34 Cr
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated revenue from operations grew 69% YoY to Rs 174.56 Cr in Q3FY26, with total income at Rs 178.34 Cr. Net profit after tax surged 105% to Rs 33.58 Cr. For 9MFY26, PAT rose 110% to Rs 84.86 Cr on revenue of Rs 474.30 Cr. EBITDA grew 87% to Rs 138 Cr in 9M. Regulated markets revenue rose 61% to Rs 112.7 Cr. Auditors flagged emphasis of matter on tax estimates.
Strong revenue and profit growth from regulated and emerging markets. Watch IPO fund utilisation, with Rs 137.88 Cr of Rs 500 Cr still unutilised.